In the DBCG HYPO trial a number of radiation therapy (RT) parameters were prospectively determined for each individual treatment plan. These parameters were reported to a database and analyzed to determine the plan quality in the trial.
Dose errors were detected in 29 patients. In 9 patients afected more than 1 session (5 patients in 2011, 3 patients in 2012, 1 patient in 2013 and no patients in 2014). The number of corrective actions has increased because of the increasing number of registered events: 2 in 2011, 4 in 2012, 7 in 2013 and 9 in 2014. Purpose or Objective: Reference dosimetry audit measurements in UK radiotherapy centres have been carried out over the last 20 years. This work examines the variation in local dosimetry calibration in a network of radiotherapy centres, draws conclusions on the implementation of an absorbed dose based protocol for MV photon beams and includes the measured effect of a change in the nationally recommended electron code of practice (CoP) from an air kerma based to an absorbed dose based protocol.
Conclusion

Material and Methods:
Data from reference dosimetry audits conducted in radiotherapy centres by the National Measurement Institute (NMI) for photon, electron and kV xrays have been collated, recording the NMI:Centre ratio for reference output measurements, beam quality, and field chamber comparison. A total of 81 MV photon, 98 electron and 30 kV photon beams were measured during 68 visits between June 1994 and February 2015. The change in the national standard deviation has been assessed over time, and differences due to the change between the two electron CoPs during this period has been quantified. The improvement in consistency for MV beams since the adoption of a CoP traceable to a primary standard of absorbed dose is assessed.
Results: The mean NMI:Centre difference for radiation output calibration was less than 0.25% for all modalities. A total of 7 measurements were reported to be outside the +/-2% tolerance.There was a statistically significant difference (p= 0.008) in the mean result for the respective air kerma based electron CoP, +0.75% (n= 14) with the absorbed dose based protocol giving +0.20% (n=84). The variation in MV results has decreased steadily over time (see Figure 1 ). The standard deviation has halved when comparing the first and last 20 results, being 0.85% (2000) and 0.35% (2015). This trend has also been noted within regional audit groups. A linear correlation was observed between the 'NMI:Centre output ratio' and the 'NMI:Centre field chamber comparison ratio'. There has been no significant difference observed between regional audit and national audit for the measured NMI:Centre ratios, but some regions have had many more NMI audits than others, some having no beams audited for a particular modality, and others having more than 20.
Conclusion: Data has been collated from 20 years of NMI reference dosimetry audits, and key trends and changes have been noted. The introduction of the 2003 absorbed dosebased electron CoP has decreased the difference between NMI and centre measured outputs. The use of a single absorbed dose based MV CoP, introduced just prior to the start of these audits, has contributed to the improved consistency demonstrated in these results. This not only shows the impact of a rigorous traceability chain developed by close collaboration between NMI and end users but also demonstrates that the NMI audit programme is likely to be a contributing factor to this improvement in consistency in dosimetry nationally.
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Results: A total of 1847 pts (904 right-sided and 943 leftsided) were treated with either 40 Gy/15 fx (912 pts) or 50 Gy/25 fx (935 pts). 388 of the left-sided pts were treated with gated RT, and 440 without. No information about gating was available for the remaining 115 pts. Dmax(CTV) was less than 110% of the prescription dose in 99.4% of the plans. More than 2 cm3 of the CTV received 107-110% of the dose in 1% of the hypo-fractionated plans. For the normofractionated plans, this deviation was observed in 3.5% of the plans. For 92.3% of the hypo-fractionated plans, less than 2% of the CTV was covered with doses above 105%, whereas 3.9% and 3.5% of the plans had minor and major deviations, respectively. For 80.8% of the pts, the part of the CTV covered with at least 95% of the prescription dose was in compliance with the guidelines. Minor and major deviations were observed for 12.6% and 6.6% of the pts, respectively. By taking laterality into consideration, 90.8% of the right-sided pts were in compliance with the guidelines compared to only 71.2% of the left-sided pts. For the left-sided pts with available information about gating, it was found that 87.4% and 59.3% of the pts treated with and without gated RT, respectively, were in compliance, thus indicating that shielding of the heart resulted in CTV under-dosage. This was supported by compliance to the protocol heart dose guidelines for 941 left-sided pts. Only one hypo-fractionated pt showed a major deviation in V35Gy and a minor deviation in V17Gy (data missing for one pt). The lung dose satisfied the protocol guidelines for 99.4% of the pts.
Conclusion:
A high degree of compliance with protocol guidelines was found for the DBCG HYPO trial. Only a few pts received CTV doses above 107% of the prescription dose. The CTV volume covered with less than 95% dose deviated from protocol guidelines for about 40% of the left-sided pts treated without gated RT. With gated RT this number decreased to about 12%, almost equal to that of right-sided pts. This indicates that gated RT for left-sided pts reduces the necessity of CTV dose compromise due to heart shielding.
EP-1937
UK stereotactic ablative radiotherapy trials normal tissue dose constraints tolerance consensus G.G. Hanna
